ROP.SW is trading 2.4% up at $335.20 after Roche reported key FDA milestones for a cancer drug and companion diagnostic, which investors appear to be viewing positively.
- The move builds on recent gains over the past two sessions, suggesting a strong company-specific catalyst tied to oncology pipeline progress.
- The advance comes despite only modest moves in broader indices, highlighting the impact of the regulatory milestones.